GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sansure Biotech Inc (SHSE:688289) » Definitions » EBIT

Sansure Biotech (SHSE:688289) EBIT : ¥277 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sansure Biotech EBIT?

Sansure Biotech's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥37 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥277 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sansure Biotech's annualized ROC % for the quarter that ended in Sep. 2024 was 1.02%. Sansure Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 9.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sansure Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2.53%.


Sansure Biotech EBIT Historical Data

The historical data trend for Sansure Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sansure Biotech EBIT Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 45.98 3,070.67 2,617.04 2,318.01 412.89

Sansure Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 244.78 59.86 97.72 81.91 37.38

Competitive Comparison of Sansure Biotech's EBIT

For the Medical Instruments & Supplies subindustry, Sansure Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sansure Biotech's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sansure Biotech's EV-to-EBIT falls into.



Sansure Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥277 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sansure Biotech  (SHSE:688289) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sansure Biotech's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=39.372 * ( 1 - 14.05% )/( (3289.236 + 3334.084)/ 2 )
=33.840234/3311.66
=1.02 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8632.08 - 624.965 - ( 4717.879 - max(0, 671.039 - 5903.884+4717.879))
=3289.236

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8571.194 - 668.31 - ( 4568.8 - max(0, 714.28 - 5742.695+4568.8))
=3334.084

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sansure Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=149.532/( ( (1034.085 + max(485.507, 0)) + (1070.437 + max(448.589, 0)) )/ 2 )
=149.532/( ( 1519.592 + 1519.026 )/ 2 )
=149.532/1519.309
=9.84 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(666.914 + 391.966 + 78.524) - (624.965 + 0 + 26.932)
=485.507

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(608.556 + 419.03 + 117.072) - (668.31 + 0 + 27.759)
=448.589

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sansure Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=276.865/10964.653
=2.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sansure Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Sansure Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sansure Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.
Executives
Tan De Yong Core technical personnel
Wang Hai Xiao senior management
Jie Ya Ping Core technical personnel
Zhang Ke Ya Core technical personnel
Yang Li Core technical personnel
Liu Rang Jiao Core technical personnel
Deng Zhong Ping Senior management, core technical personnel
Zhou Jun senior management
Zhu Jian senior management
Wu Kang Core technical personnel
Xiong Xiao Yan senior management
Ji Bo Zhi Core technical personnel
Mou Wei Min Core technical personnel
Ren Xiao Mei Core technical personnel
Liu Kai senior management

Sansure Biotech Headlines

No Headlines